These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 22473713)
1. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study. Manns MP; Gane E; Rodriguez-Torres M; Stoehr A; Yeh CT; Marcellin P; Wiedmann RT; Hwang PM; Caro L; Barnard RJ; Lee AW; Hepatology; 2012 Sep; 56(3):884-93. PubMed ID: 22473713 [TBL] [Abstract][Full Text] [Related]
2. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. Hayashi N; Mobashery N; Izumi N J Gastroenterol; 2015 Feb; 50(2):238-48. PubMed ID: 25115901 [TBL] [Abstract][Full Text] [Related]
3. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. Hayashi N; Nakamuta M; Takehara T; Kumada H; Takase A; Howe AY; Ludmerer SW; Mobashery N J Gastroenterol; 2016 Apr; 51(4):390-403. PubMed ID: 26403160 [TBL] [Abstract][Full Text] [Related]
4. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. Lawitz E; Rodriguez-Torres M; Stoehr A; Gane EJ; Serfaty L; Bhanja S; Barnard RJ; An D; Gress J; Hwang P; Mobashery N J Hepatol; 2013 Jul; 59(1):11-7. PubMed ID: 23439259 [TBL] [Abstract][Full Text] [Related]
5. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224 [TBL] [Abstract][Full Text] [Related]
6. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481 [TBL] [Abstract][Full Text] [Related]
7. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225 [TBL] [Abstract][Full Text] [Related]
8. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408 [TBL] [Abstract][Full Text] [Related]
9. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies. Kumada H; Mochida S; Suzuki F; Chayama K; Karino Y; Nakamura K; Fujimoto G; Howe AY; Ludmerer SW; Mobashery N J Gastroenterol Hepatol; 2016 Oct; 31(10):1674-1683. PubMed ID: 26936417 [TBL] [Abstract][Full Text] [Related]
10. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. Hayashi N; Izumi N; Kumada H; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Ki R; Komada Y; Seto C; Goto S J Hepatol; 2014 Aug; 61(2):219-27. PubMed ID: 24727123 [TBL] [Abstract][Full Text] [Related]
11. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG; Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040 [TBL] [Abstract][Full Text] [Related]
12. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Fried MW; Buti M; Dore GJ; Flisiak R; Ferenci P; Jacobson I; Marcellin P; Manns M; Nikitin I; Poordad F; Sherman M; Zeuzem S; Scott J; Gilles L; Lenz O; Peeters M; Sekar V; De Smedt G; Beumont-Mauviel M Hepatology; 2013 Dec; 58(6):1918-29. PubMed ID: 23907700 [TBL] [Abstract][Full Text] [Related]
13. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Pockros PJ; Jensen D; Tsai N; Taylor R; Ramji A; Cooper C; Dickson R; Tice A; Kulkarni R; Vierling JM; Lou Munson M; Chen YC; Najera I; Thommes J; Hepatology; 2013 Aug; 58(2):514-23. PubMed ID: 23359491 [TBL] [Abstract][Full Text] [Related]
14. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV; Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427 [TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects. Gardner S; Cutrell A; Elko-Simms C; Adkison K; Hamatake R; Walker J; Rodriguez-Torres M; Hong Z Liver Int; 2014 Jul; 34(6):e89-95. PubMed ID: 24107072 [TBL] [Abstract][Full Text] [Related]
16. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658 [TBL] [Abstract][Full Text] [Related]
17. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. Ferenci P; Asselah T; Foster GR; Zeuzem S; Sarrazin C; Moreno C; Ouzan D; Maevskaya M; Calinas F; Morano LE; Crespo J; Dufour JF; Bourlière M; Agarwal K; Forton D; Schuchmann M; Zehnter E; Nishiguchi S; Omata M; Kukolj G; Datsenko Y; Garcia M; Scherer J; Quinson AM; Stern JO; J Hepatol; 2015 Jun; 62(6):1246-55. PubMed ID: 25559324 [TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. Rodriguez-Torres M; Lawitz E; Kowdley KV; Nelson DR; Dejesus E; McHutchison JG; Cornpropst MT; Mader M; Albanis E; Jiang D; Hebner CM; Symonds WT; Berrey MM; Lalezari J J Hepatol; 2013 Apr; 58(4):663-8. PubMed ID: 23183528 [TBL] [Abstract][Full Text] [Related]